These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 16540013)

  • 21. Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma.
    Gordon LI; Witzig TE; Wiseman GA; Flinn IW; Spies SS; Silverman DH; Emmanouilides C; Cripe L; Saleh M; Czuczman MS; Olejnik T; White CA; Grillo-López AJ
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):87-92. PubMed ID: 11842394
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of nuclear medicine in the treatment of non-Hodgkin's lymphoma (NHL).
    Bischof Delaloye A
    Leuk Lymphoma; 2003; 44 Suppl 4():S29-36. PubMed ID: 15154740
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma.
    Meredith RF; Knox SJ
    Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S15-22. PubMed ID: 16979433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma.
    Gordon LI; Witzig T; Molina A; Czuczman M; Emmanouilides C; Joyce R; Vo K; Theuer C; Pohlman B; Bartlett N; Wiseman G; Darif M; White C
    Clin Lymphoma; 2004 Sep; 5(2):98-101. PubMed ID: 15453924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.
    Marcus R
    Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody.
    Wiseman GA; White CA; Witzig TE; Gordon LI; Emmanouilides C; Raubitschek A; Janakiraman N; Gutheil J; Schilder RJ; Spies S; Silverman DH; Grillo-López AJ
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3281s-3286s. PubMed ID: 10541376
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiobiology of radioimmunotherapy with 90Y ibritumomab tiuxetan (Zevalin).
    Hernandez MC; Knox SJ
    Semin Oncol; 2003 Dec; 30(6 Suppl 17):6-10. PubMed ID: 14710397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-myeloablative radioimmunotherapy for non-Hodgkin's lymphoma.
    Schaefer-Cutillo J; Friedberg JW
    Semin Hematol; 2008 Apr; 45(2):110-7. PubMed ID: 18381106
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Contribution of radioimmunotherapy to the treatment of lymphoma].
    Rizzo-Padoin N
    Ann Pharm Fr; 2008; 66(5-6):300-8. PubMed ID: 19061730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma.
    Ansell SM; Ristow KM; Habermann TM; Wiseman GA; Witzig TE
    J Clin Oncol; 2002 Sep; 20(18):3885-90. PubMed ID: 12228209
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma.
    Weigert O; Illidge T; Hiddemann W; Dreyling M
    Cancer; 2006 Aug; 107(4):686-95. PubMed ID: 16826593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma.
    Schnell R; Dietlein M; Schomäcker K; Kobe C; Borchmann P; Schicha H; Hallek M; Engert A
    Onkologie; 2008 Feb; 31(1-2):49-51. PubMed ID: 18268399
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors associated with toxicity and response to yttrium 90-labeled ibritumomab tiuxetan in patients with indolent non-Hodgkin's lymphoma.
    Borghaei H; Wallace SG; Schilder RJ
    Clin Lymphoma; 2004 Oct; 5 Suppl 1():S16-21. PubMed ID: 15498145
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 90Y-ibritumomab tiuxetan: rationale for patient selection in the treatment of indolent non-Hodgkin's lymphoma.
    Grillo-López AJ
    Semin Oncol; 2005 Feb; 32(1 Suppl 1):S44-9. PubMed ID: 15786025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia.
    Schilder R; Molina A; Bartlett N; Witzig T; Gordon L; Murray J; Spies S; Wang H; Wiseman G; White C
    Cancer Biother Radiopharm; 2004 Aug; 19(4):478-81. PubMed ID: 15453962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Radioimmunotherapy in non-Hodgkin's lymphoma. With focus on anti-CD20 treatment].
    de Nully Brown P; Jurlander J; Lindén O; Hansen M
    Ugeskr Laeger; 2005 Oct; 167(41):3867-9. PubMed ID: 16221425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma.
    Winter JN
    Clin Lymphoma; 2004 Oct; 5 Suppl 1():S22-6. PubMed ID: 15498146
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nursing a patient during and after 90Y-ibritumomab tiuxetan (Zevalin) therapy.
    Clayton J
    Leuk Lymphoma; 2003; 44 Suppl 4():S49-55. PubMed ID: 15154742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Wiseman GA; White CA; Sparks RB; Erwin WD; Podoloff DA; Lamonica D; Bartlett NL; Parker JA; Dunn WL; Spies SM; Belanger R; Witzig TE; Leigh BR
    Crit Rev Oncol Hematol; 2001; 39(1-2):181-94. PubMed ID: 11418315
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New strategies in radioimmunotherapy for lymphoma.
    Pandit-Taskar N; Hamlin PA; Reyes S; Larson SM; Divgi CR
    Curr Oncol Rep; 2003 Sep; 5(5):364-71. PubMed ID: 12895386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.